Personalis, Inc. (PSNL), a cancer genomics company on Tuesday said it entered into an agreement with ClearNote Health, Inc., a cancer detection company, to expand the epigenomic 5- hydroxymethylcytosine or 5hmC platform.
The company stated that the technology would accelerate the development of personalized cancer therapies as it tracks changes in 5hmC levels with the help of AI-based analytical methods, which would detect cancer earlier.
Currently, Personalis' stock is trading at $1.49, down 2.61 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.